MaxCyte, Inc.: quarterly results

MXCTNASDAQHealthcare · Services-Commercial Physical & Biological Research

Price

$1.19

November 13, 2026Market cap $127M

DCF calculator

What Ploutos Investor adds for MaxCyte

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 7 fiscal years, from 2019
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Results, quarter by quarter

When the company put out each quarter's results (its 8-K, item 2.02), what they showed against the same quarter a year before, and how the stock moved on the first session after.

Nov 10, 2026 last results

Next results

in 88 daysAround Feb 11, 2027 · for Q4 2026

last Nov 10, 2026next Feb 11, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

The first session after results

±19.1%average move, either way

3 times upof the last 41 times down

Largest: +29.7% on Oct 14, 2026 (Q3 2026).

How the stock moved after each release

The close of the first session after the results against the close before them.

MXCT that sessionS&P 500 the same day

Every release

Revenue and diluted EPS of the quarter reported, with the change against the same quarter a year before.

  • Q3 2026
    Stock, next session-13.1%
  • Q3 2026
    Stock, next session+29.7%
  • Q2 2026
    Stock, next session+9.4%
  • Q1 2026
    Stock, next session+24.1%

Every release

MXCT's results days and the share's move after each, from Q2 2021 to Q4 2025, 28 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 8 quarters.

Times are the SEC's acceptance of the 8-K, in New York time: before 16:00 the market traded on it that day, after it the next day. A move on a results day has other causes too, and says nothing about the next one.

The full analysis

What do MaxCyte's filings show?

The results say what MaxCyte reported. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.